ABSTRACT
Precise control of gene expression is an invaluable tool in studying development and other physiological processes. Other applications for regulated gene expression include inducible gene targeting, overexpression of toxic and teratogenic genes, antisense RNA expression, and gene therapy (1) . For cultured cells, glucocorticoids and other steroids are commonly used to induce expression of a desired gene. In the past several years, a tetracycline-regulated system has been devised in which gene activity is induced in the absence of the antibiotic and is repressed in its presence (2) (3) (4) (5) . Recently, the tetracycline-based system has been utilized in transgenic mice (4, 5) . Disadvantages to this system include the continuous treatment of tetracycline to repress expression and the slow clearance of antibiotic from bone, which interferes with quick and precise inductions. While this system has been improved by the recent identification of a mutant tetracycline repressor, which acts conversely as an inducible activator, the pharmacokinetics of tetracycline may hinder its use during development when a precise and efficient on-off switch is essential (6) .
As an alternative to tetracycline, we have explored the use of the insect molting hormone ecdysone as a potential inducer. A pulse of the steroid hormone ecdysone triggers metamorphosis in Drosophila melanogaster, showing genomic effects such as chromosomal puffing within minutes of hormone addition (7) (8) (9) . Mediating this response is the functional ecdysone receptor, a heterodimer of the ecdysone receptor (EcR) and the product of the ultraspiracle gene (USP) (10, 11 MATERIALS AND METHODS Plasmids. CMX-EcR, CMX-USP, CMX-FXR, CMXhRXRa, EcREx5-AMTV-Luc, CMX-GEcR, MMTV-Luc, and CMX-GR have been described (10, 12) . CMX-VpEcR was constructed by ligation of an EcoRI fragment of psk-EcR and CMX-Vpl6. CMX-VgEcR was generated by site-directed mutagenesis of CMX-VpEcR using the transformer mutagenesis kit (Clontech) and the mutagenic oligonucleotide 5'-TACAACGCCCTCACCTGTGGATCCTGCAAGG-TGTTTCTTTCGACGCAGC-3'. Mutagenesis of VpEcR to VgEcR altered the P box region of the DNA binding domain of EcR to resemble that of the glucocorticoid receptor (GR) (13) . The following amino acids were altered: E282G, G283S, and G286V. EcREx4-AHSP-f3gal was constructed by oligomerizing two annealed oligonucleotides containing the HSPEcRE (10 (10, 11) (Fig. 1A) . To maximize the sensitivity of an ecdysone-inducible system, modifications of EcR were made. The N-terminal transactivation domain of EcR was replaced by the corresponding domain of GR (Fig.  1D ). This new hybrid receptor named GEcR boosted muristerone responsiveness from 3-to 11-fold in a transient transfection assay (Fig. 1A) . Replacement of EcR's natural heterodimeric partner, USP, by its mammalian homologue, the retinoid X receptor (RXR), produced a more potent liganddependent heterodimer, producing a 34-fold induction (Fig.  1A) . A most potent heterodimer, however, was a combination of RXR and VpEcR, an N-terminal truncation of EcR attached to the VP16 activation domain resulting in a 212-fold induction ( Fig. 1 A and D) . Different from most nuclear receptor/VP16 fusion proteins, which exhibit high constitutive activity, VpEcR generates ligand-dependent superinduction while maintaining a very low basal activity (15, 16) . In addition, the reporter vector was also modified by inserting consensus binding sites for the ubiquitous transcription factor Spl between the minimal promoter and the ecdysone response elements (EcREs). Spl has been shown to boost transcriptional activity of many promoters (17) (18) (19) . The addition of Spl sites to the ecdysone responsive promoter increases the absolute activity 5-fold (Fig. 1A) . (Fig. 1B) . This response element is a hybrid between the glucocorticoid response element (GRE) (Fig. 2) . X-Gal staining of one stable cell clone, N13, was performed. After 24 hr of treatment with 1 ,uM muristerone, 100% of the cells turned dark blue with 3 hr of staining (Fig. 3 A and B) . Dose-response curves of stably integrated X3-gal and luciferase reporters in N13 cells revealed Muristerone activity in mice. Adult mice were injected intraperitoneally with sesame oil with or without 10 mg of muristerone. After 12 hr, blood was drawn from the mice, and the serum was isolated. Serum from sesame oil-injected mice was divided, and half was supplemented with muristerone to a final concentration of 10 ,uM.
The three batches of mouse serum were diluted 1:10 in DMEM and placed onto CV-1 cells transfected with CMX-GEcR, CMX-hRXRa, and EcREx5-AMTV-Luc. that inducibility approaching 3 orders of magnitude can be achieved at a final concentration of 10 ,tM muristerone (Fig.  3C) . One-hundred-fold induction was achieved by muristerone concentrations as low as 100 nM (Fig. 3C) . Finally, the kinetics of muristerone-mediated induction was measured. Inductions of 100-fold in 3 hr, 1000-fold in 8 hr, and maximal effects of 20,000-fold after 20 hr of treatment were seen (Fig. 3D) (Fig. 4) In contrast to tetracycline-based systems, steroids like ecdysone offer pharmacokinetics that allow for both fast distribution and clearance of the inducer. In a direct comparison, VgEcR/RXR demonstrated both lower basal activity and higher inducibility than tTA or rtTA. Finally, in conjunction with the tetracycline-based systems, the ecdysone-inducible Reporter: TETREx7-tk-luc TETREx7-tk-luc TETREx7-tk-uc E/GREx4-MTV-uc E/GREx4-MTV-uc 
